Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol on Neurocognitive Processes in OUD
NCT04982029Phase 2Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Apr 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in opioid use disorder (OUD) comparing Cannabidiol 600mg with Placebo (2 arms). Primary endpoint: Change in Cue-reactivity. Started Apr 2022; status: completed.
02
Drugs
cannabidiol
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT04982029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04982029.